A preliminary investigation of α-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 28, Issue 2, 2008, Pages 138-146

  Kim, Eosu ^b   Park, Dong Wha ^b   Choi, Song Hee ^b   Kim, Jae Jin ^b   Cho, Hyun Sang ^a  

^a Yonsei University College of Medicine   (South Korea)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUOXETINE; LITHIUM; RISPERIDONE; THIOCTIC ACID; VALPROATE SEMISODIUM;

ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; BRIEF PSYCHIATRIC RATING SCALE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG MECHANISM; FEMALE; HUMAN; INSULIN RESISTANCE; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; APPETITE; BLOOD GLUCOSE; BODY MASS INDEX; BRIEF PSYCHIATRIC RATING SCALE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DEPRESSION; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; OBESITY; RECURRENCE; SCHIZOPHRENIA; THIOCTIC ACID; TRIGLYCERIDES; WEIGHT LOSS;

EID: 40949103157     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31816777f7     Document Type: Article

References (57)

1. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001;101:277-288.
2. Werneke U, Taylor D, Sanders TA. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol. 2002;17:145-160.
3. Kahn BB, Alquier T, Carling D, et al. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1:15-25.
4. Kola B, Boscaro M, Rutter GA, et al. Expanding role of AMPK in endocrinology. Trends Endocrinol Metab. 2006;17:205-215.
5. Minokoshi Y, Alquier T, Furukawa N, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 2004;428:569-574.
6. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes. 2004;53:S143-S151.
7. Cui W, Paglialunga S, Kalant D, et al. Acylation stimulating protein/C5L2 neutralizing antibodies alter triglyceride metabolism in vitro and in vivo. Am J Physiol Endocrinol Metab. 2007;293:E1482-E1491.
8. Kubota N, Yano W, Kubota T, et al. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab. 2007;6:55-68.
9. Kim MS, Park JY, Namkoong C, et al. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med. 2004;10:727-733.
10. Packer L, Witt EH, Tritschler HJ. alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19:227-250.
11. Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res. 1999;31:171-179.
12. Kamenova P. Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. Hormones (Athens). 2006;5:251-258.
13. Holmquist L, Stuchbury G, Berbaum K, et al. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther. 2007;113:154-164.
14. Pershadsingh HA. Alpha-lipoic acid: physiologic mechanisms and indications for the treatment of metabolic syndrome. Expert Opin Investig Drugs. 2007;16:291-302.
15. Liu J. The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochem Res. 2008;33:194-203.
16. Yadav V, Marracci G, Lovera J, et al. Lipoic acid in multiple sclerosis: a pilot study. Mult Scler. 2005;11:159-165.
17. Song KH, Lee WJ, Koh JM, et al. Alpha-Lipoic acid prevents diabetes mellitus in diabetes-prone obese rats. Biochem Biophys Res Commun. 2005;326:197-202.
18. Lee Y, Naseem RH, Park BH, et al. Alpha-lipoic acid prevents lipotoxic cardiomyopathy in acyl CoA-synthase transgenic mice. Biochem Biophys Res Commun. 2006;344:446-452.
19. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277:925-926.
20. Flemenbaum A, Zimmermann RL. Inter- and intra-rater reliability of the Brief Psychiatric Rating Scale. Psychol Rep. 1973;32:783-792.
21. Montgomery SA, Smeyatsky N, de Ruiter M, et al. Profiles of antidepressant activity with the Montgomery-Asberg Depression Rating Scale. Acta Psychiatr Scand Suppl. 1985;320:38-42.
22. Salazar MR. Alpha lipoic acid: a novel treatment for depression. Med Hypotheses. 2000;55:510-512.
23. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
24. O'Brien PC, Zhang D, Bailey KR. Semi-parametric and non-parametric methods for clinical trials with incomplete data. Stat Med. 2005;24:341-358.
25. Lee WJ, Song KH, Koh EH, et al. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun. 2005;332:885-891.
26. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19 Suppl 1:1-93.
27. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62:19-28.
28. Dwyer DS, Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav. 2003;75:255-260.
29. Estrada DE, Ewart HS, Tsakiridis T, et al. Stimulation of glucose uptake by the natural coenzyme alpha-lipoic acid/thioctic acid: participation of elements of the insulin signaling pathway. Diabetes. 1996;45:1798-1804.
30. Kim MS, Lee KU. Role of hypothalamic 5′-AMP-activated protein kinase in the regulation of food intake and energy homeostasis. J Mol Med. 2005;83:514-520.
31. Cohn G, Valdes G, Capuzzi DM. Pathophysiology and treatment of the dyslipidemia of insulin resistance. Curr Cardiol Rep. 2001;3:416-423.
32. Hamano Y. Effects of dietary lipoic acid on plasma lipid, in vivo insulin sensitivity, metabolic response to corticosterone and in vitro lipolysis in broiler chickens. Br J Nutr. 2006;95:1094-1101.
33. Zong H, Ren JM, Young LH, et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci U S A. 2002;99:15983-15987.
34. Taflinski T, Chojnacka J. Sibutramine-associated psychotic episode. Am J Psychiatry. 2000;157:2057-2058.
35. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121-2134.
36. Kim SF, Huang AS, Snowman AM, et al. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A. 2007;104:3456-3459.
37. Cremer DR, Rabeler R, Roberts A, et al. Safety evaluation of alpha-lipoic acid (ALA). Regul Toxicol Pharmacol. 2006;46:29-41.
38. Hahm JR, Kim BJ, Kim KW. Clinical experience with thioctacid (thioctic acid) in the treatment of distal symmetric polyneuropathy in Korean diabetic patients. J Diabetes Complications. 2004;18:79-85.
39. De Leon J. Glucuronidation enzymes, genes and psychiatry. Int J Neuropsychopharmacol. 2003;6:57-72.
40. Flier J, Van Muiswinkel FL, Jongenelen CA, et al. The neuroprotective antioxidant alpha-lipoic acid induces detoxication enzymes in cultured astroglial cells. Free Radic Res. 2002;36:695-699.
41. Balijepalli S, Kenchappa RS, Boyd MR, et al. Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics. Neurochem Int. 2001;38:425-435.
42. Maurer I, Moller HJ. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol Cell Biochem. 1997;174:255-259.
43. Casademont J, Garrabou G, Miro O, et al. Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. J Clin Psychopharmacol. 2007;27:284-288.
44. Stoll S, Hartmann H, Cohen SA, et al. The potent free radical scavenger alpha-lipoic acid improves memory in aged mice: putative relationship to NMDA receptor deficits. Pharmacol Biochem Behav. 1993;46:799-805.
45. Zhang L, Xing GQ, Barker JL, et al. Alpha-lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway. Neurosci Lett. 2001;312:125-128.
46. Kang HJ, Noh JS, Bae YS, et al. Calcium-dependent prevention of neuronal apoptosis by lithium ion: essential role of phosphoinositide 3-kinase and phospholipase Cgamma. Mol Pharmacol. 2003;64:228-234.
47. Arivazhagan P, Panneerselvam C. Alpha-lipoic acid increases Na+K+ATPase activity and reduces lipofuscin accumulation in discrete brain regions of aged rats. Ann N Y Acad Sci. 2004;1019:350-354.
48. Suh JH, Moreau R, Heath SH, et al. Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep. 2005;10:52-60.
49. Sachdev P. Tardive akathisia, tardive dyskinesia, and serum iron status. J Clin Psychopharmacol. 1994;14:147-149.
50. Wang SJ, Chen HH. Presynaptic mechanisms underlying the alpha-lipoic acid facilitation of glutamate exocytosis in rat cerebral cortex nerve terminals. Neurochem Int. 2007;50:51-60.
51. Schreibelt G, Musters RJ, Reijerkerk A, et al. Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity. J Immunol. 2006;177:2630-2637.
52. Freeman MP, Hibbeln JR, Wisner KL, et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry. 2006;67:1954-1967.
53. Hallahan B, Hibbeln JR, Davis JM, et al. Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial. Br J Psychiatry. 2007;190:118-122.
54. Akbar M, Calderon F, Wen Z, et al. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci U S A. 2005;102:10858-10863.
55. Zhang WJ, Wei H, Hagen T, et al. Alpha-lipoic acid attenuates LPS-induced inflammatory responses by activating the phosphoinositide 3-kinase/Akt signaling pathway. Proc Natl Acad Sci U S A. 2007;104:4077-4082.
56. Biessels GJ, Smale S, Duis SE, et al. The effect of gamma-linolenic acid-alpha-lipoic acid on functional deficits in the peripheral and central nervous system of streptozotocin-diabetic rats. J Neurol Sci. 2001;182:99-106.
57. 2. J Biochem Mol Biol. 2002;35:547-552.